In a report released today, Difei Yang from Mizuho Securities reiterated a Hold rating on Alder Biopharmaceuticals (ALDR), with a price target of $15. The company’s shares closed yesterday at $9.11, close to its 52-week low of $8.65.
According to TipRanks.com, Yang is a 4-star analyst with an average return of 5.5% and a 39.1% success rate. Yang covers the Healthcare sector, focusing on stocks such as Xeris Pharmaceuticals Inc, Audentes Therapeutics, and Revance Therapeutics.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Alder Biopharmaceuticals with a $21 average price target.
See today’s analyst top recommended stocks >>
Based on Alder Biopharmaceuticals’ latest earnings release for the quarter ending March 31, the company reported a quarterly GAAP net loss of $118 million. In comparison, last year the company had a GAAP net loss of $68.39 million.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Alder Biopharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which discovers, develops and commercializes various therapeutic antibodies. Its product portfolio includes ALD1910, a preclinical product candidate also in development as a migraine prevention therapy.
